Literature DB >> 11751710

Participation of the hypothalamus-hypophysis axis in the sympathetic activation of human obesity.

G Grassi1, G Seravalle, R Dell'Oro, C Turri, L Pasqualinotto, M Colombo, G Mancia.   

Abstract

Previous studies have shown that hypothalamic and hypophyseal factors are involved in the acute sympathoexcitation induced by a variety of laboratory stimuli. Whether a chronic condition of sympathetic activation, such as that characterizing human obesity, is also dependent on these factors has never been investigated. In 40 normotensive obese subjects ([mean+/-SEM] age, 39.1+/-0.8 years) we measured blood pressure (Finapres), heart rate (ECG), and postganglionic muscle sympathetic nerve activity (MSNA) (microneurography). In 20 subjects measurements were repeated, according to a double-blind randomized sequence, after a midnight oral dose of dexamethasone (1 mg) (n=10) or placebo (n=10), while in the remaining subjects they were performed again after 1 week of a daily evening oral administration of 1 mg of dexamethasone (n=10) or placebo (n=10). The same protocol was performed in 16 age-matched lean normotensives. In both groups acute dexamethasone administration markedly reduced plasma cortisol (radioimmunoassay), without affecting hemodynamic and neural variables. In contrast to the acute administration, in obese subjects prolonged dexamethasone administration, although not affecting blood pressure and heart rate, significantly reduced both plasma cortisol (from 16.0+/-1.3 to 0.7+/-0.1 microg/dL; P<0.01) and MSNA (from 59.5+/-2.8 to 39.6+/-2.9 bursts per 100 heartbeats; P<0.02; -33.1+/-4.1%). This was not the case in lean subjects, in which the dexamethasone-induced reduction in plasma cortisol was associated with a slight and nonsignificant MSNA decrease. In both lean and obese subjects, placebo administration caused no change in any variable. Thus, prolonged dexamethasone administration exerts in obese subjects marked sympathoinhibitory effects that are not detectable in lean individuals. This suggests that hypothalamic and hypophyseal factors substantially contribute to the sympathoexcitation of obesity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751710     DOI: 10.1161/hy1201.096117

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

Review 1.  The global epidemic of obesity: are we becoming more sympathetic?

Authors:  Kevin P Davy
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

Review 2.  Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications.

Authors:  Graziela Z Kalil; William G Haynes
Journal:  Hypertens Res       Date:  2011-11-03       Impact factor: 3.872

3.  The potential role of increased adrenal volume in the pathophysiology of obesity-related type 2 diabetes.

Authors:  A F Godoy-Matos; A R Vieira; R O Moreira; W F Coutinho; L M Carraro; D M Moreira; R Pasquali; R M R Meirelles
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

4.  Experimental Weight Gain Increases Ambulatory Blood Pressure in Healthy Subjects: Implications of Visceral Fat Accumulation.

Authors:  Naima Covassin; Fatima H Sert-Kuniyoshi; Prachi Singh; Abel Romero-Corral; Diane E Davison; Francisco Lopez-Jimenez; Michael D Jensen; Virend K Somers
Journal:  Mayo Clin Proc       Date:  2018-05       Impact factor: 7.616

5.  Symptoms of anxiety and mood disturbance alter cardiac and peripheral autonomic control in patients with metabolic syndrome.

Authors:  Edgar Toschi-Dias; Ivani C Trombetta; Valdo José Dias da Silva; Cristiane Maki-Nunes; Maria Janieire N N Alves; Luciana F Angelo; Felipe X Cepeda; Daniel G Martinez; Carlos Eduardo Negrão; Maria Urbana P B Rondon
Journal:  Eur J Appl Physiol       Date:  2012-08-24       Impact factor: 3.078

Review 6.  Impact of the obesity epidemic on hypertension and renal disease.

Authors:  John E Hall; Daniel W Jones; Jay J Kuo; Alexandre da Silva; Lakshmi S Tallam; Jiankang Liu
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

Review 7.  Sympathetic nervous system behavior in human obesity.

Authors:  Kevin P Davy; Jeb S Orr
Journal:  Neurosci Biobehav Rev       Date:  2008-05-28       Impact factor: 8.989

Review 8.  Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome.

Authors:  Alicia A Thorp; Markus P Schlaich
Journal:  J Diabetes Res       Date:  2015-04-30       Impact factor: 4.011

9.  Regulators of human white adipose browning: evidence for sympathetic control and sexual dimorphic responses to sprint interval training.

Authors:  Rebecca L Scalzo; Garrett L Peltonen; Gregory R Giordano; Scott E Binns; Anna L Klochak; Hunter L R Paris; Melani M Schweder; Steve E Szallar; Lacey M Wood; Dennis G Larson; Gary J Luckasen; Matthew S Hickey; Christopher Bell
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

10.  Acute cyclooxygenase inhibition does not alter muscle sympathetic nerve activity or forearm vasodilator responsiveness in lean and obese adults.

Authors:  Jill N Barnes; Nisha Charkoudian; Luke J Matzek; Christopher P Johnson; Michael J Joyner; Timothy B Curry
Journal:  Physiol Rep       Date:  2014-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.